VANDA PHARMACEUTICALS INC. Operating Leases, Rent Expense
VANDA PHARMACEUTICALS INC. (VNDA) reported Operating Leases, Rent Expense of $3.60 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2021-02-11
- VANDA PHARMACEUTICALS INC. operating leases, rent expense for the quarter ending 2018-12-31 was $900.00K, a 12.50% increase year-over-year.
- VANDA PHARMACEUTICALS INC. operating leases, rent expense for the quarter ending 2018-09-30 was $900.00K, a 12.50% increase year-over-year.
- VANDA PHARMACEUTICALS INC. operating leases, rent expense for the quarter ending 2018-06-30 was $900.00K, a 12.50% increase year-over-year.
- VANDA PHARMACEUTICALS INC. operating leases, rent expense for the quarter ending 2018-03-31 was $900.00K, a 12.50% increase year-over-year.
- VANDA PHARMACEUTICALS INC. operating leases, rent expense for fiscal 2018 was $3.60M, a 12.50% increase from fiscal 2017.
- VANDA PHARMACEUTICALS INC. operating leases, rent expense for fiscal 2017 was $3.20M, a 28.00% increase from fiscal 2016.
- VANDA PHARMACEUTICALS INC. operating leases, rent expense for fiscal 2016 was $2.50M, a 31.58% increase from fiscal 2015.
- VANDA PHARMACEUTICALS INC. operating leases, rent expense for fiscal 2015 was $1.90M, a 11.76% increase from fiscal 2014.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 3 month as first filed | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $1.80M derived: sum of 2 quarters · filed 2021-02-11 | $2.70M derived: sum of 3 quarters · filed 2021-02-11 | $3.60M 10-K · filed 2021-02-11 | |
| 2018-09-30 | $900.00K 10-Q · filed 2019-11-07 | $1.80M derived: sum of 2 quarters · filed 2019-11-07 | $2.70M 10-Q · filed 2019-11-07 | $3.50M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-06-30 | $900.00K 10-Q · filed 2019-08-01 | $1.80M 10-Q · filed 2019-08-01 | $2.60M derived: sum of 3 quarters · filed 2020-02-26 | $3.40M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-03-31 | $900.00K 10-Q · filed 2019-05-03 | $1.70M derived: sum of 2 quarters · filed 2020-02-26 | $2.50M derived: sum of 3 quarters · filed 2020-02-26 | $3.30M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2017-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $1.60M derived: sum of 2 quarters · filed 2020-02-26 | $2.40M derived: sum of 3 quarters · filed 2020-02-26 | $3.20M 10-K · filed 2020-02-26 | |
| 2017-09-30 | $800.00K 10-Q · filed 2018-11-07 | $1.60M derived: sum of 2 quarters · filed 2018-11-07 | $2.40M 10-Q · filed 2018-11-07 | $3.20M derived: sum of 4 quarters · filed 2019-02-19 | |
| 2017-06-30 | $800.00K 10-Q · filed 2018-08-02 | $1.60M 10-Q · filed 2018-08-02 | $2.40M derived: sum of 3 quarters · filed 2019-02-19 | $3.10M derived: sum of 4 quarters · filed 2019-02-19 | |
| 2017-03-31 | $800.00K 10-Q · filed 2018-05-02 | $1.60M derived: sum of 2 quarters · filed 2019-02-19 | $2.30M derived: sum of 3 quarters · filed 2019-02-19 | $2.80M derived: sum of 4 quarters · filed 2019-02-19 | |
| 2016-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $1.50M derived: sum of 2 quarters · filed 2019-02-19 | $2.00M derived: sum of 3 quarters · filed 2019-02-19 | $2.50M 10-K · filed 2019-02-19 | |
| 2016-09-30 | $700.00K 10-Q · filed 2017-11-08 | $1.20M derived: sum of 2 quarters · filed 2017-11-08 | $1.70M 10-Q · filed 2017-11-08 | $2.20M derived: sum of 4 quarters · filed 2018-02-15 | |
| 2016-06-30 | $500.00K 10-Q · filed 2017-08-03 | $1.00M 10-Q · filed 2017-08-03 | $1.50M derived: sum of 3 quarters · filed 2018-02-15 | $2.00M derived: sum of 4 quarters · filed 2018-02-15 | |
| 2016-03-31 | $500.00K 10-Q · filed 2017-05-03 | $1.00M derived: sum of 2 quarters · filed 2018-02-15 | $1.50M derived: sum of 3 quarters · filed 2018-02-15 | $2.00M derived: sum of 4 quarters · filed 2018-02-15 | |
| 2015-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $1.00M derived: sum of 2 quarters · filed 2018-02-15 | $1.50M derived: sum of 3 quarters · filed 2018-02-15 | $1.90M 10-K · filed 2018-02-15 | |
| 2015-09-30 | $500.00K 10-Q · filed 2016-11-03 | $1.00M derived: sum of 2 quarters · filed 2016-11-03 | $1.40M 10-Q · filed 2016-11-03 | $1.90M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-06-30 | $500.00K 10-Q · filed 2016-07-28 | $900.00K 10-Q · filed 2016-07-28 | $1.40M derived: sum of 3 quarters · filed 2017-02-17 | $1.80M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-03-31 | $400.00K 10-Q · filed 2016-05-05 | $900.00K derived: sum of 2 quarters · filed 2017-02-17 | $1.30M derived: sum of 3 quarters · filed 2017-02-17 | $1.70M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $900.00K derived: sum of 2 quarters · filed 2017-02-17 | $1.30M derived: sum of 3 quarters · filed 2017-02-17 | $1.70M 10-K · filed 2017-02-17 | |
| 2014-09-30 | $400.00K 10-Q · filed 2015-11-04 | $800.00K derived: sum of 2 quarters · filed 2015-11-04 | $1.20M 10-Q · filed 2015-11-04 | $1.50M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2014-06-30 | $400.00K 10-Q · filed 2015-07-31 | $800.00K 10-Q · filed 2015-07-31 | $1.10M derived: sum of 3 quarters · filed 2016-02-12 | $1.40M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2014-03-31 | $400.00K 10-Q · filed 2015-05-07 | $700.00K derived: sum of 2 quarters · filed 2016-02-12 | $1.00M derived: sum of 3 quarters · filed 2016-02-12 | $1.30M derived: sum of 4 quarters · filed 2016-02-12 | |
| 2013-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $600.00K derived: sum of 2 quarters · filed 2016-02-12 | $900.00K derived: sum of 3 quarters · filed 2016-02-12 | $1.10M 10-K · filed 2016-02-12 | |
| 2013-09-30 | $300.00K 10-Q · filed 2014-10-27 | $600.00K derived: sum of 2 quarters · filed 2014-10-27 | $800.00K 10-Q · filed 2014-10-27 | $1.00M derived: sum of 4 quarters · filed 2015-03-13 | |
| 2013-06-30 | $300.00K 10-Q · filed 2014-08-08 | $500.00K 10-Q · filed 2014-08-08 | $700.00K derived: sum of 3 quarters · filed 2015-03-13 | $900.00K derived: sum of 4 quarters · filed 2015-03-13 | |
| 2013-03-31 | $200.00K 10-Q · filed 2014-05-08 | $400.00K derived: sum of 2 quarters · filed 2015-03-13 | $600.00K derived: sum of 3 quarters · filed 2015-03-13 | $800.00K derived: sum of 4 quarters · filed 2015-03-13 | |
| 2012-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $400.00K derived: sum of 2 quarters · filed 2015-03-13 | $600.00K derived: sum of 3 quarters · filed 2015-03-13 | $2.00M 10-K · filed 2015-03-13 | |
| 2012-09-30 | $200.00K 10-Q · filed 2013-11-08 | $400.00K derived: sum of 2 quarters · filed 2013-11-08 | $1.80M 10-Q · filed 2013-11-08 | $3.00M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-06-30 | $200.00K 10-Q · filed 2013-07-31 | $1.60M 10-Q · filed 2013-07-31 | $2.80M derived: sum of 3 quarters · filed 2014-02-25 | $3.20M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-03-31 | $1.40M 10-Q · filed 2013-05-10 | $800.00K 10-Q · filed 2012-08-03 | $2.60M derived: sum of 2 quarters · filed 2014-02-25 | $3.00M derived: sum of 3 quarters · filed 2014-02-25 | |
| 2011-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $1.60M derived: sum of 2 quarters · filed 2014-02-25 | $2.10M 10-K · filed 2014-02-25 | ||
| 2011-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $900.00K 10-Q · filed 2012-11-08 | |||
| 2011-06-30 | $500.00K 10-Q · filed 2012-08-03 | ||||
| 2010-12-31 | $1.00M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |